Vilobelimab Antibody

SKU: orb1980486

Description

Vilobelimab (CaCP-29) is a chimeric monoclonal antibody that specifically inhibits the complement protein C5a, thereby blocking neutrophil activation. It is a valuable research tool for investigating mechanisms of systemic inflammation, including in models of severe COVID-19 and other complement-mediated pathologies, in both in vitro and in vivo experimental settings.

Research Area

Immunology & Inflammation, Infectious Disease & Virology

Images & Validation

−

Key Properties

−

CAS Number	2250440-41-4
MW	145.86 kDa
Purity	95.00%
Target	Complement System,SARS-CoV

Bioactivity

−

In Vitro	Vilobelimab selectively neutralizes C5a in a dose-dependent manner without preventing the formation of membrane-attacking complexes and has not raised significant safety concerns in certain clinical studies in patients with severe sepsis and septic shock. Read more...

Storage & Handling

−

Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

IFX1, IFX-1, CaCP29, CaCP-29, ComplementSystem, complement 5a receptor (C5aR), Complement System, SARSCoV, SARS-CoV

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Quick Database Links

Gene Symbol

Complement System,SARS-CoV

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols